I hear from patients with serious life-threatening conditions, constituents in north Texas, being frustrated with what they see as a regulatory barrier from trying and experimenting with new therapies when all others have failed them.
Burgess addresses patient frustrations over regulatory barriers to accessing new therapies.
Share
More from Michael Burgess
I urge all my fellow colleagues to join me in supporting H.R. 766 and ensuring that we continue to prioritize preventive healthcare initiatives for the betterment of all Americans, and I reserve the balance of my time.
I never expected that CMMI was actually going to deliver the cost savings that was promised.
For the purpose of debate only, I yield the customary 30 minutes to the Congresswoman from Pennsylvania (Ms. Scanlon), pending which I yield myself such time as I may consume. During consideration of this resolution, all time yielded is…
I will simply underscore the fact that entry- level chemists at the EPA are hired at much higher than the GSA rate. These are not highly sought-after scientists. These are entry-level applicants, and there is no shortage of applicants for…
Other voices in this conversation
